Eli Lilly and Company needed a new ELN that was GxP validation-ready, scalable for a global workforce, and capable of integrating with existing software while adding robust compliance features. Revvity Signals provided a cloud-based ELN that met these requirements with a user-friendly interface to promote rapid adoption and minimize IT workload. The platform supported seamless integrations, delivered comprehensive GxP controls, and offered flexible configuration to align with evolving research needs across sites. By standardizing data capture, ensuring traceability, and enabling compliant workflows, Signals helped Lilly maintain compliant operations, reduce risk, and accelerate pharmaceutical development without disrupting ongoing programs.

Join for free to read